ALKERMES | ALKS - Net Income


ALKERMES reported $16.29M in Net Income for its fiscal quarter ending in September of 2026.





Net Income Change Date
AbbVie USD 4.22B 605M Sep/2026
Acadia Pharmaceuticals USD 53.52M 22.02M Sep/2026
ALKERMES USD 16.29M 15.79M Sep/2026
Amgen USD 3.86B 1.49B Sep/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD -122.83M 167.59M Sep/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.1B 301M Jun/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -87M 27.65M Sep/2026
J&J USD 210M 5.32B Sep/2026
Malin Corporation EUR -1.1M 2.2M Dec/2023
Merck USD 5.07B 6.4B Sep/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 206.5M 62.1M Sep/2026
Otsuka Holdings JPY 106.49B 10.77B Sep/2026
Ovoca Bio EUR 4.42M 5.19M Dec/2025
Pfizer USD 3.24B 3.49B Sep/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Vertex Pharmaceuticals USD 653.6M 446.2M Sep/2026